QURE News and Press, uniQure N.V. From 03/17/22

uniQure (QURE +4.2%) is trading higher for the third straight session after UBS upgraded the shares of the Dutch biotech to Buy from Neutral, citing an attractive long-term risk-reward profile ahead of key milestones expected in the next 1 – 2 years. The analysts led by Eliana Merle po...

Pharma/biotech is undervalued by about 14% relative to 11-year averages. Life science tools and healthcare equipment are overvalued by over 25%. Focus on IXJ: a more diversified alternative to XLV. 10 stocks cheaper than their peers in March. For further details see: ...

NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems&#x...

uniQure press release (NASDAQ:QURE): FY GAAP EPS of $7.04 beats by $0.96. Revenue of $524M (+1297.0% Y/Y) beats by $56.66M. As of December 31, 2021, the Company had cash and cash equivalents of $556.3 million. For further details see: uniQure GAAP EPS of $7.04 beats by $0.96, revenue of...

~ Data from largest gene therapy study in hemophilia B showed sustained therapeutic effect at 18-months and statistical superiority in reducing annualized bleeding rate compared to baseline FIX prophylactic therapy; Submissions of marketing applications on track for the first half of 2022...

The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February

LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the dosing of the first two patients in its European open-label Phase ...

Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022 - Data from the largest gene therapy study in Hemophilia B to date shows that etranacogene dezapa...

Investors were all spooked today with Dow plummeting more than 500 points. The primary cause can be attributed to inflation fears, disappointing earnings, and booming bond yields. Tech stocks drove the Dow down with the NASDAQ skidding 2.6 percent and the S&P 500 index falling 1.8 percent...

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...